55results about "Growth hormones" patented technology

The present technology generally relates to peptides that bind to the growth hormone receptor (GhR), to peptides that bind to the GhR and have antagonistic activity, and to compositions comprising such peptides.

The invention belongs to the technical field of biological medicines, and discloses a novel long-acting recombinant human growth hormone fusion protein. The fusion protein is obtained by fusion expression of human growth hormone (hGH) and an anti-human albumin nano antibody (VHH). And the long-acting principle is that the clearance rate is reduced by reversibly and widely combining with albumin with endogenous circulation. The fusion protein has the characteristics that 1, the fusion protein is obtained by fusion expression of two functional domains of hGH and VHH, hGH sequence mutation and complex chemical modification are not involved, the preparation method is simpler, and the sample uniformity is better; 2, in the fusion protein, the N end of the hGH protein has no additional structure, and the VHH functional domain is connected to the C end of the hGH, so that the influence on the activity of the hGH is reduced; and 3, animal efficacy results show that the fusion protein has a long-acting effect.

To provide pharmaceutical formulations for the treatment of diseases which can be treated with human growth hormone (hGH), and methods of the treatment, the formulations keeping the injection volume low to ensure administration of a drug in a manner convenient for a patient.SOLUTION: The present invention provides a polymeric human growth hormone prodrug, and a dry pharmaceutical formulation, a liquid pharmaceutical formulation and a reconstituted pharmaceutical formulation that comprise the prodrug. The present invention further provides the use thereof as medicaments for the treatment of diseases which can be treated with growth hormone, and methods of the treatment. The present invention also provides methods of application of such a polymeric human growth hormone prodrug or pharmaceutical formulation.SELECTED DRAWING: None

To provide nucleic acids (including AAV expression cassettes), AAV vectors, and compositions for use in methods of treating and / or delaying the onset of diseases associated with mutations in mecp2 genes, such as Rett Syndrome.SOLUTION: Also provided herein are methods for treating a brain-derived neurotrophic factor (BDNF) - associated disease and / or delaying the onset of a brain-derived neurotrophic factor (BDNF) - associated disease. The present disclosure provides a nucleic acid comprising an adeno-associated virus (AAV) expression cassette, wherein the AAV expression cassette comprises, in a 5' to 3' direction, a 5' inverted terminal repeat (ITR), a synthetic activity-dependent promoter, a Rett syndrome-associated gene, and a 3' ITR.SELECTED DRAWING: None

A linker for linking a therapeutic agent to another moiety, such as the Fc region of an antibody. A linker having two or more maleimide functional groups capable of undergoing a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by conjugating it to a novel linker and the Fc region of an antibody. An antibody-drug conjugate having an increased duration of action over the drug alone.

This disclosure provides engineered aminoacyl tRNA synthetases and tRNAs for efficient production of proteins containing non-standard amino acids. These engineered orthogonal tRNA (O-tRNA) / orthogonal aminoacyl tRNA synthetase (O-RS) pairs, i.e., Orthogonal Translation Systems (OTSs) can be used to incorporate a non-standard amino acid in a specific position in a growing polypeptide in response to a selector codon that is recognized by the engineered tRNA.

The present invention relates to a solid oral pharmaceutical composition comprising (i) a core comprising a peptide or protein drug, and (ii) a first coating, wherein the first coating comprises a copolymer (A) in combination with a copolymer (B) and / or a copolymer (C) and / or a copolymer (D).

The invention discloses a method for recombinant gene protein of sebastes schlegeli growth hormone, and belongs to the technical field of gene engineering. The sebastes schlegeli growth hormone gene is subjected to escherichia coli expression whole gene modification, and a label for 6Xhis purification is added; then, a recombinant escherichia coli (BL21 (DE3) / pET-28a) prokaryotic expression system is constructed, and sebastes schlegeli growth hormone fusion protein is expressed. The purified sebastes schlegeli growth hormone fusion protein is fed to fishes, and the average weight gain rate of the fishes is remarkably higher than that of a control group (Plt; 0.001), the average feed conversion ratio (FCR) is significantly reduced to 1.28 (Plt; the sebastes schlegeli growth hormone fusion protein prepared by the method provided by the invention has the advantages that the growth factor of the sebastes schlegeli growth hormone fusion protein is greatly improved, the feed utilization efficiency is obviously improved, the obtained sebastes schlegeli growth hormone fusion protein has a growth promoting effect, various risks caused by long breeding time are reduced, and the sebastes schlegeli growth hormone fusion protein shows a certain commercial application value.

The present invention relates to the fields of biotechnology and aquaculture, and in particular to a method for increasing the growth rate of fishes. The method comprises the following steps: fusing a coding region of a gh1 gene with a strong promoter of another endogenous highly-expressed gene in vivo, without introducing an exogenous gene, to generate a gh1 highly-expressed gene, wherein the strong promoter is a β-actin gene promoter. The present invention can create fast-growing fish species.

This application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated recombinant receptor-binding domain (RBD-S) of the S glycoprotein of SARS-CoV-2 (severe acute respiratory syndrome-associated coronavirus 2), a nucleic acid encoding the RBD-S of SARS-CoV-2, expression cassettes and vectors based thereon, and a recombinant AAV5 (adeno-associated virus serotype 5)-based virus for inducing SARS-CoV-2-specific immunity and / or preventing SARS-CoV-2-related coronavirus infection, an AAV5-based vaccine for inducing SARS-CoV-2-specific immunity and / or preventing SARS-CoV-2-related coronavirus infection, and uses thereof for inducing SARS-CoV-2-specific immunity and / or preventing SARS-CoV-2-related coronavirus infection.

The present disclosure provides an artificial recombinant protein for improving the performance of an active protein or polypeptide and the use thereof. The present disclosure provides a polypeptide unit (U) or a polypeptide complex unit (PU) that is very effective for prolonging the biological activity and half-life of a protein or polypeptide or improving the in-vivo and in-vitro properties of a protein or polypeptide, the polypeptide unit (U) being mainly composed of proline (P), alanine (A) and glutamic acid (E). The present disclosure also provides a biologically active fusion protein comprising the polypeptide unit (U) or the polypeptide complex unit (PU) and an active protein or polypeptide connected thereto.

To provide effective, shelf-stable and safe biological preparations such as peptides and proteins for non-invasive delivery.SOLUTION: The present invention relates to a pharmaceutical composition for transmucosal administration, comprising a peptide drug or a protein drug in combination with an excipient with a pKa value of 12 or higher.SELECTED DRAWING: None

To provide a long-acting growth hormone that demonstrates efficacy outcomes superior to daily somatropin.SOLUTION: The present invention provides a long-acting growth hormone or a pharmaceutical formulation comprising such a long-acting growth hormone for use in a method of reducing the percentage of non-responding individuals in a patient population suffering from growth hormone deficiency.SELECTED DRAWING: None

The invention belongs to the technical field of biological medicine and nano-drug delivery, and particularly relates to a long-acting growth hormone (hGH) wrapped bacterial outer membrane vesicle and application, and the outer membrane vesicle GH-OMVs wraps a human growth hormone mutant with an amino acid sequence shown as SEQ ID NO: 1. The GH-OMVs provided by the invention can be used for preparing medicines or preparations for preventing and / or treating diseases related to growth hormone deficiency or growth hormone-related metabolic disorder, including but not limited to growth hormone deficiency, dwarf / low height, osteoporosis and the like, and has a good clinical application prospect.

Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.

The present application relates to a kind of Fc mutant, fusion protein, nucleic acid molecule, expression vector, recombinant cell, pharmaceutical composition and its purposes.Fc mutant has the amino acid sequence as any one of SEQ ID NO:3~7;Fusion protein includes: second peptide segment, second peptide segment is the functional region of bioactive molecule, third peptide segment, third peptide segment includes the amino acid sequence shown in SEQ ID NO:2 or the Fc mutant of preceding, second peptide segment is connected with third peptide segment.The Fc mutant of the present application is monomer form, fusion protein has higher in vitro and in vivo activity and lower ADCC, CDC effect, can effectively treat growth hormone deficiency.

The present invention provides a sustained-release formulation of human growth hormone that can be administered at high concentrations and in injection volumes of less than 1.0 mL for a variety of indications requiring human growth hormone therapy. The present invention relates to human growth hormone polymer prodrugs, as well as dry, liquid and reconstituted pharmaceutical formulations comprising said prodrugs. The invention further relates to their use as medicaments for treating diseases treatable by growth hormone, and to methods of treatment. The invention also relates to methods of administering such human growth hormone polymer prodrugs or pharmaceutical formulations.

The present invention relates to long-acting growth hormone receptor antagonists comprising a growth hormone variant and an albumin binding moiety. Further described are processes for the preparation of said compounds and their use in medicine, for example for the treatment of acral hypertrophy.

A composition for use in treating a coagulation or clotting disorder, treating excessive bleeding or bruising, or maintaining homeostasis following a mild to moderate bleed in a subject, the composition comprising a human chorionic gonadotropin carboxy terminal peptide (CTP)-modified human active Factor VII (FVIIa) polypeptide comprising three CTP molecules attached in tandem to the C-terminal end of FVIIa and having the amino acid sequence of SEQ ID NO: 7, wherein the CTP-modified FVIIa polypeptide is in a substantially pure and active form, the CTP-modified FVIIa polypeptide having a high sialic acid content of at least 15 mol / mol

The invention belongs to the technical field of animal genetic engineering, and particularly relates to a method for increasing the growth speed of pigs. The method comprises the following steps that under the condition that an exogenous gene is not introduced, a coding region of a GH1 gene and a strong promoter of another endogenous high-expression gene are fused in vivo, the GH1 high-expression gene is generated, and the strong promoter is a PSMC5 gene promoter, an ACTA1 gene promoter, an ACTB gene promoter, an NME2 gene promoter or an RPL23 gene promoter. According to the method, pig varieties which grow rapidly can be created.

A synthetic peptide construct comprises an amino acid sequence-RLIEDICLPRWGCLWEDD (SEQ ID NO: 2) (also known as “GLYCLOK”), a flexible, hydrophilic glycine-serine (Gly-Ser) linker, and a polypeptide chain between 25 to 70 amino acids in length, which incorporates an albumin-binding moiety with a dissociation constant (Kd) to albumin of less than 20 nanomolar (nM). This construct may include the sequence RLIEDICLPRWGCLWEDD (SEQ. ID NO: 2) within its terminal 25 amino acids. The albumin-binding moiety may be cyclic, with a disulfide bond formed by at least one cysteine residue. The constructs is used as an agonist to modulate receptor interactions in vivo, enhancing therapeutic efficacy and extending circulating half-life in mammals, including humans. The peptides exhibit significant binding to albumin, enhancing bioavailability and therapeutic duration.

The invention discloses a method for recombinant gene protein of Atlantic salmon growth hormone, and belongs to the technical field of gene engineering. Escherichia coli expression whole gene modification is carried out on an Atlantic salmon growth hormone gene, then a modified connecting pET-28a (+) plasmid is introduced into an Escherichia coli BL21 (DE3) strain, a recombinant Escherichia coli (BL21 (DE3) / pET-28a) expression line is constructed, and an Atlantic salmon growth hormone (rSGH) fusion protein is expressed. After the Atlantic salmon growth stimulating fusion protein is purified, auxin capable of promoting the growth of the Atlantic salmon is prepared, then the pure Atlantic salmon growth stimulating fusion protein is fed to fishes, the weight gain rate of the fishes is 16.8% higher than that of a control group, and the feed conversion rate is 21.7% higher. It is proved that the purified Atlantic salmon growth hormone (rSGH) fusion protein has a growth promoting effect and shows a certain commercial application value.

A method for treating growth hormone deficiency, including administering a human growth hormone fusion protein (GX-H9). A method includes administering a pharmaceutical composition containing an hGH fusion protein (GX-H9) and a pharmaceutically acceptable carrier, wherein the fusion protein (GX-H9) is administered once a week at a dose of 0.4 to 1.6 mg per body weight kg of a pediatric patient, or administered once every two weeks at a dose of 0.8 to 3.2 mg per body weight kg of a pediatric patient.

The invention discloses a preparation method and application of an inclusion body based on double promoter expression plasmids, and belongs to the technical field of biology. The method comprises the following steps: screening all-potent nuclease, purifying all-potent nuclease, verifying degradation activity of all-potent nuclease DNS on nucleic acid, constructing a double-promoter recombinant strain, culturing in a fermentation tank, recovering thalli, and crushing the thalli to obtain an inclusion body crude product. The T7 promoter is used for inducing high-efficiency expression of the recombinant human growth hormone gene, the cspA promoter is used for inducing high-activity expression of the totipotent nuclease gene DNS, the application effect in the recombinant human growth hormone is remarkable, in the preparation process, the thallus viscosity is low, the homogenate crushing effect is improved, the BL21 (DE3) / DGH thallus crushing rate is high, and the application range is wide. The content of inclusion bodies harvested by centrifuging fermentation liquor in unit volume is high, the residual quantity of HCD (host DNA residues) in target protein in unit mass is reduced, and the energy consumption is effectively reduced.

The invention discloses an affinity chromatography method for purifying human growth hormone and a DARPin dimer ligand. The DARPin dimer comprises a first DARPin monomer and a second DARPin monomer which are connected through a connecting peptide or a disulfide bond; each DARPin monomer is provided with a four-section type structure of an N-cap, a first internal repeated module IR1, a second internal repeated module IR2 and a C-cap; the amino acid sequence of the DARPin monomer is selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5 in a sequence list, and the amino acid sequence of the DARPin monomer has 90%-98% sequence identity with any amino acid sequence selected from the list. According to the present invention, through the design of the DARPin dimer ligand having the N-cap, the first internal repeating module IR1, the second internal repeating module IR2 and the C-cap four-segment structure, and the directed random mutation of the IR1 / IR2 region, the novel ligand having high affinity and high specificity on the human growth hormone is obtained, and the non-specific binding of the host protein and the structure-similar impurities is significantly reduced;

The invention relates to a long-acting growth hormone receptor antagonist comprising a growth hormone variant and an albumin binding moiety. Further described are methods of preparing said compound and use thereof in medicine e.g., for the treatment of acromegaly.

A combination of medications and medication doses is disclosed whereby age-related changes in systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color, thymotrophic hormones, immune cell populations, the CD4 / CD8 cell ratio, bone marrow density, thymus structure, kidney function, and epigenetic age can be reversed in humans. Surprisingly, agents that accelerate the growth of cells reduce cancer risk, agents that intensify immune responses attenuate age-related inflammation, agents with no prior connection to hair color reverse age-related hair whitening, and a combination of agents that induces IGF-1, a hormone previously thought to drive systemic aging, results in a reversal of systemic aging as documented by an epigenetic clock. Medication combinations useful in the present invention include human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin.

The present invention provides a fusion polypeptide, the fusion polypeptide targeting both GLP-1 receptors (GLP-1R) and growth hormone receptors (GHR). The present invention provides polynucleotides encoding the fusion polypeptide, vectors expressing the fusion polypeptide and / or comprising the polynucleotides, as well as cells expressing the polynucleotides and / or comprising the vectors. The present invention also provides methods of preparing the fusion polypeptide and use of the fusion polypeptide in the manufacture of a medicament. Also provided are methods of treatment and fusion polypeptides for use in therapy.

The invention belongs to the field of biotechnology and aquaculture, and particularly relates to a method for increasing the growth speed of fishes. The method comprises the following steps that under the condition that an exogenous gene is not introduced, a coding region of a gh1 gene and a strong promoter of another endogenous high-expression gene are fused in vivo, the gh1 high-expression gene is generated, and the strong promoter is a beta-actin gene promoter. Fish varieties which grow rapidly can be created.